NCT00004444已完成不适用
Pilot Randomized Study of Paromomycin (Aminosidine) vs Streptomycin for Uncomplicated Pulmonary Tuberculosis
FDA Office of Orphan Products Development0 个研究点目标入组 24 人开始时间: 1994年11月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 24
研究概览
简要总结
OBJECTIVES: I. Compare the pharmacokinetics and early bactericidal activity of paromomycin (aminosidine) vs streptomycin for the treatment of uncomplicated pulmonary tuberculosis.
II. Compare the tolerability of these two drugs in these patients. III. Establish the relationships between achieved serum concentration, minimal inhibitory concentration, and early bactericidal activity of paromomycin and streptomycin.
详细描述
PROTOCOL OUTLINE: This is a randomized study. Patients are randomized to one of three treatment arms. Patients in arms I and II receive one of two doses of paromomycin intramuscularly once a day for 3 days. Patients in arm III receive streptomycin intramuscularly once a day for 3 days. All patients then begin a course of standard therapy for tuberculosis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •PROTOCOL ENTRY CRITERIA:
- •-Disease Characteristics--
- •Microbiologically proven uncomplicated pulmonary tuberculosis Positive direct sputum smear for acid-fast bacilli OR Presumptive diagnosis based on clinical and radiological findings
- •No known risk factors for multidrug resistant tuberculosis (MDR TB) including: Domicile, shelter, or prison exposure to MDR TB within 6 months Residence in a specific domicile, shelter, or prison cell block within 6 months of a known outbreak of MDR TB Hospitalization, within 6 months, on a medical service or unit in which nosocomial transmission of MDR TB is known to have occurred
- •No clinical evidence of CNS or miliary tuberculosis
- •HIV seronegative
- •-Prior/Concurrent Therapy--
- •Biologic therapy: At least 12 weeks since immune modulators (including colony-stimulating factors, interferons, or interleukins)
- •Chemotherapy: No concurrent chemotherapy
- •Endocrine therapy: At least 12 weeks since corticosteroids
- •Other: At least 2 years since treatment or prophylaxis for tuberculosis At least 12 weeks since treatment with any drug with activity against tuberculosis, including: All standard drugs used for tuberculosis Clofazimine Rifabutin Quinolones Aminoglycosides At least 12 weeks since pentoxifylline
- •-Patient Characteristics--
- •Hematopoietic: Absolute neutrophil count at least 1,000/mm3
- •Renal: Creatinine clearance greater than 60 mL/min
- •Pulmonary: No chronic obstructive pulmonary disease
- •Other: Not pregnant Fertile patients must use effective contraception No history of intolerance or known hypersensitivity to aminoglycosides No known or suspected Mycobacterium avium complex infection No other serious, acute infection No diabetes No major organ dysfunction No malignancy requiring chemotherapy
排除标准
- 未提供
研究者
相似试验
已完成
1 期
Comparison of Antibiotics for Pseudomonas in Early CFCystic FibrosisNCT00823238University of North Carolina, Chapel Hill21
已完成
2 期
Phase 2 Trial to Evaluate the Early Bactericidal Activity, Safety and Tolerability of Meropenem Plus Amoxycillin/CA and Faropenem Plus Amoxycillin/CA in Adult Patients With Newly Diagnosed Pulmonary TuberculosisPulmonary TuberculosisNCT02349841TASK Applied Science46
已完成
不适用
Pharmacokinetic Study of Antibiotics in Patients Assisted by Extracorporeal Membrane Oxygenation (PHARMECMO)Extracorporeal Membrane OxygenationIntensive Care UnitAntibioticsSepsisNCT03131063Groupe Hospitalier Pitie-Salpetriere45
已完成
2 期
Early Bactericidal Activity of TBA-7371 in Pulmonary TuberculosisPulmonary TuberculosisNCT04176250Bill & Melinda Gates Medical Research Institute93
已完成
2 期
Early Bactericidal Activity, Safety & Tolerability of Oral GSK3036656 in a Dual Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin Susceptible Pulmonary TuberculosisTuberculosisNCT05382312GlaxoSmithKline127